Spero Therapeutics (SPRO) Revenue & Revenue Breakdown
Spero Therapeutics Revenue Highlights
Latest Revenue (Y)
$66.80M
Latest Revenue (Q)
$11.80M
Main Segment (Y)
Collaboration Revenue Related Party
Spero Therapeutics Revenue by Period
Spero Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $66.80M | 39.24% |
| 2024-12-31 | $47.98M | -53.77% |
| 2023-12-31 | $103.78M | 113.63% |
| 2022-12-31 | $48.58M | 1482.38% |
| 2021-12-31 | $3.07M | -67.10% |
| 2020-12-31 | $9.33M | -48.59% |
| 2019-12-31 | $18.15M | 357.56% |
| 2018-12-31 | $3.97M | 100.40% |
| 2017-12-31 | $1.98M | 490.75% |
| 2016-12-31 | $335.00K | 100.00% |
| 2015-12-31 | - | - |
Spero Therapeutics generated $66.80M in revenue during NA 2025, up 39.24% compared to the previous quarter, and up 715.99% compared to the same period a year ago.
Spero Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $11.80M | 100.92% |
| 2025-03-31 | $5.87M | -37.22% |
| 2024-12-31 | $9.36M | -30.54% |
| 2024-09-30 | $13.47M | 123.85% |
| 2024-06-30 | $6.02M | 43.13% |
| 2024-03-31 | $4.20M | -94.15% |
| 2023-12-31 | $71.83M | 181.97% |
| 2023-09-30 | $25.47M | 3132.61% |
| 2023-06-30 | $788.00K | 6.49% |
| 2023-03-31 | $740.00K | -98.40% |
| 2022-12-31 | $46.30M | 4179.26% |
| 2022-09-30 | $1.08M | 20.76% |
| 2022-06-30 | $896.00K | 262.75% |
| 2022-03-31 | $247.00K | -91.00% |
| 2021-12-31 | $2.74M | -10.44% |
| 2021-09-30 | $3.06M | -40.48% |
| 2021-06-30 | $5.15M | -29.48% |
| 2021-03-31 | $7.30M | 282.80% |
| 2020-12-31 | $1.91M | -52.27% |
| 2020-09-30 | $4.00M | 131.33% |
| 2020-06-30 | $1.73M | 921.89% |
| 2020-03-31 | $169.00K | -75.72% |
| 2019-12-31 | $696.00K | 304.65% |
| 2019-09-30 | $172.00K | -92.02% |
| 2019-06-30 | $2.16M | -43.37% |
| 2019-03-31 | $3.81M | 125.00% |
| 2018-12-31 | $1.69M | 157.14% |
| 2018-09-30 | $658.00K | 42.12% |
| 2018-06-30 | $463.00K | -59.84% |
| 2018-03-31 | $1.15M | 16.11% |
| 2017-12-31 | $993.00K | 66.33% |
| 2017-09-30 | $597.00K | 139.76% |
| 2017-06-30 | $249.00K | 77.86% |
| 2017-03-31 | $140.00K | -58.21% |
| 2016-12-31 | $335.00K | 100.00% |
| 2016-09-30 | - | - |
Spero Therapeutics generated $11.80M in revenue during Q2 2025, up 100.92% compared to the previous quarter, and up 280.73% compared to the same period a year ago.
Spero Therapeutics Revenue Breakdown
Spero Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Collaboration Revenue Related Party | $47.03M | $27.02M |
| Grant Revenue | $7.18M | $20.58M |
| Collaboration Revenue | $12.59M | $371.00K |
Spero Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Collaboration Revenue Related Party (70.41%), Collaboration Revenue (18.84%), and Grant Revenue (10.75%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|---|
| Grant Revenue | $1.64M | $2.39M | $2.39M | $763.00K |
| Collaboration Revenue Related Party | $27.08M | $3.05M | $11.80M | $5.10M |
| Collaboration Revenue | $12.57M | $12.00K | - | - |
Spero Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Collaboration Revenue Related Party (65.58%), Collaboration Revenue (30.45%), and Grant Revenue (3.97%).
Spero Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SPRO | Spero Therapeutics | $66.80M | $11.80M |
| SEER | Seer | $16.58M | $4.12M |
| VTGN | VistaGen Therapeutics | $1.06M | $303.00K |
| MCRB | Seres Therapeutics | $789.00K | $351.00K |
| ACTU | Actuate Therapeutics | - | - |
| IRD | Opus Genetics | - | - |
| CRBP | Corbus Pharmaceuticals | - | - |
| INO | Inovio Pharmaceuticals | - | - |
| CGTX | Cognition Therapeutics | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| HURA | TuHURA Biosciences | - | - |